These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22829656)

  • 1. Effects of cancer-associated EPHA3 mutations on lung cancer.
    Zhuang G; Song W; Amato K; Hwang Y; Lee K; Boothby M; Ye F; Guo Y; Shyr Y; Lin L; Carbone DP; Brantley-Sieders DM; Chen J
    J Natl Cancer Inst; 2012 Aug; 104(15):1182-97. PubMed ID: 22829656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
    Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
    Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform.
    Quinn AM; Hickson N; Adaway M; Priest L; Jaeger E; Udar N; Keeling C; Kamieniorz M; Dive C; Wallace A; Byers RJ; Newman WG; Nonaka D; Blackhall FH
    J Thorac Oncol; 2015 May; 10(5):784-792. PubMed ID: 25634010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis.
    Lahtela J; Pradhan B; Närhi K; Hemmes A; Särkioja M; Kovanen PE; Brown A; Verschuren EW
    Dis Model Mech; 2015 Apr; 8(4):393-401. PubMed ID: 25713296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 7. Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival.
    Xi HQ; Wu XS; Wei B; Chen L
    J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22350700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
    Yu JA; Li H; Meng X; Fullerton DA; Nemenoff RA; Mitchell JD; Weyant MJ
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1479-85. PubMed ID: 23026567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.
    Chang CC; Lin MT; Lin BR; Jeng YM; Chen ST; Chu CY; Chen RJ; Chang KJ; Yang PC; Kuo ML
    J Natl Cancer Inst; 2006 Jul; 98(14):984-95. PubMed ID: 16849681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.
    Andretta E; Cartón-García F; Martínez-Barriocanal Á; de Marcondes PG; Jimenez-Flores LM; Macaya I; Bazzocco S; Bilic J; Rodrigues P; Nieto R; Landolfi S; Ramon Y Cajal S; Schwartz S; Brown A; Dopeso H; Arango D
    Sci Rep; 2017 Feb; 7():41576. PubMed ID: 28169277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference with netrin-1 and tumor cell death in non-small cell lung cancer.
    Delloye-Bourgeois C; Brambilla E; Coissieux MM; Guenebeaud C; Pedeux R; Firlej V; Cabon F; Brambilla C; Mehlen P; Bernet A
    J Natl Cancer Inst; 2009 Feb; 101(4):237-47. PubMed ID: 19211441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
    Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
    Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers.
    Wood LD; Calhoun ES; Silliman N; Ptak J; Szabo S; Powell SM; Riggins GJ; Wang TL; Yan H; Gazdar A; Kern SE; Pennacchio L; Kinzler KW; Vogelstein B; Velculescu VE
    Hum Mutat; 2006 Oct; 27(10):1060-1. PubMed ID: 16941478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics.
    London M; Gallo E
    Mol Biol Rep; 2020 Jul; 47(7):5523-5533. PubMed ID: 32621117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3.
    Lahtela J; Corson LB; Hemmes A; Brauer MJ; Koopal S; Lee J; Hunsaker TL; Jackson PK; Verschuren EW
    Cell Cycle; 2013 Feb; 12(4):625-34. PubMed ID: 23324396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STIP overexpression confers oncogenic potential to human non-small cell lung cancer cells by regulating cell cycle and apoptosis.
    Tang Y; Yan G; Song X; Wu K; Li Z; Yang C; Deng T; Sun Y; Hu X; Yang C; Bai H; Li H; Tan W; Ye M; Liu J
    J Cell Mol Med; 2015 Dec; 19(12):2806-17. PubMed ID: 26354852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo.
    Verone-Boyle AR; Shoemaker S; Attwood K; Morrison CD; Makowski AJ; Battaglia S; Hershberger PA
    Oncotarget; 2016 Jan; 7(1):995-1013. PubMed ID: 26654942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.